Shots:

• The P-III A4091058 study involves assessing of Tanezumab (2.5 & 5mg- q8w) vs NSAIDS (naproxen 500 mg/celecoxib 100 mg/diclofenac extended release 75 mg- q2d) in 3-021 patients with moderate-to-severe OA in ratio 1:1:1 for 56wks. across globe + 24-week safety follow-up study
• The P-III A4091058 results: composite 1EPs for safety (3.8% & 7.1% vs 1.5%); incidence of RPOA (3.2% & 6.3% vs 1.2%); joint replacement (5.3% & 8.0% vs 2.6%); subchondral fracture (6&7 vs 4) no pathological fracture observed; one case of osteonecrosis with tanezumab 5 mg
• Tanezumab is a mAb that selectively targets nerve growth factor (NGF) act against pain without producing addiction and has received FDA’s FT designation for OA and chronic low back pain

Ref: Pfizer | Image: The Telegraph